PRESS RELEASE published on 05/04/2023 at 12:30, 2 years 10 months ago Moderna Reports First Quarter 2023 Financial Results and Provides Business Updates
PRESS RELEASE published on 05/03/2023 at 22:05, 2 years 10 months ago Moderna Announces Phase 1/2 Data on mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA) to be Presented at the 2023 ASGCT Annual Meeting
PRESS RELEASE published on 05/02/2023 at 23:15, 2 years 10 months ago Moderna Announces Establishment of an Enterprise Solutions Hub and Commercial Operations in The Philippines
PRESS RELEASE published on 04/20/2023 at 22:05, 2 years 11 months ago Moderna to Report First Quarter 2023 Financial Results on Thursday, May 4, 2023
PRESS RELEASE published on 04/20/2023 at 13:30, 2 years 11 months ago Moderna and IBM to Explore Quantum Computing and Generative AI for mRNA Science
PRESS RELEASE published on 04/16/2023 at 17:00, 2 years 11 months ago Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following C
PRESS RELEASE published on 04/11/2023 at 13:00, 2 years 11 months ago Moderna Announces Clinical and Program Updates at 4th Vaccines Day
PRESS RELEASE published on 04/06/2023 at 23:00, 2 years 11 months ago MRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV Melan
PRESS RELEASE published on 03/30/2023 at 13:00, 2 years 11 months ago Moderna Finalizes Agreement with the Government of the Republic of Kenya to Establish an mRNA Manufacturing Facility
PRESS RELEASE published on 03/24/2023 at 12:30, 3 years ago Moderna to Host Fourth Annual Virtual Vaccines Day on April 11, 2023
Published on 03/27/2026 at 11:00, 21 minutes ago RE Royalties Announces Strategic Review to Evaluate Path for Long-Term Value Creation
Published on 03/27/2026 at 09:30, 1 hour 51 minutes ago Amap Street Stars Launches Macao Authentic Delicacies Ranking to Drive Cultural-Tourism Innovation in the Greater Bay Area
Published on 03/27/2026 at 08:05, 3 hours 16 minutes ago Battery X Metals Announces Corporate Awareness Engagements
Published on 03/26/2026 at 23:00, 12 hours 21 minutes ago FutureGen Industries Announces Closing of Debt Settlement
Published on 03/26/2026 at 22:05, 13 hours 16 minutes ago BlackBerry to Announce Fourth Quarter and Fiscal Year 2026 Results on April 9, 2026
Published on 03/27/2026 at 10:45, 36 minutes ago Athora Group completes acquisition of Pension Insurance Corporation Group and announces plans to relocate headquarters to the UK
Published on 03/27/2026 at 10:40, 41 minutes ago Shreehas Tambe Appointed CEO & Managing Director of Biocon Limited, Effective April 1, 2026
Published on 03/27/2026 at 10:23, 57 minutes ago Original-Research: HORNBACH Holding AG & Co. KGaA (von Quirin Privatbank Kapitalmarktgeschäft): Buy
Published on 03/27/2026 at 10:00, 1 hour 21 minutes ago AlphaPet Ventures welcomes Cpro Food, one of the leading super-premium brands for dog and cat food in Belgium
Published on 03/27/2026 at 09:45, 1 hour 36 minutes ago DESTINUS Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026
Published on 03/27/2026 at 07:00, 4 hours 21 minutes ago WEB SA - CONVOCATION ASSEMBLEE GENERALE ORDINAIRE EXERCICE 2025 - 28/04/2026
Published on 03/26/2026 at 18:17, 17 hours 4 minutes ago Eiffage se renforce au capital de Getlink et porte sa participation à 29,40 % du capital
Published on 03/26/2026 at 18:17, 17 hours 4 minutes ago Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 18:00, 17 hours 21 minutes ago Arrêté des comptes au 31 décembre 2025 et perspectives 2026
